You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

News Room




October 1, 2020

Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines. Read More

June 29, 2020

Repligen Announces Agreement to Acquire Engineered Molding Technology. Read More

April 26, 2019

Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies.  Read More

Septermber 4, 2018

Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors. Read More

June 28, 2018

Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand.  Read More

June 27, 2018

Repligen Announces Agreement with Navigo Proteins for the Exclusice Co-Development of Next Generation Affinity Ligands.  Read More

June 23, 2017

Repligen Corporation and Spectrum Inc. to Join Forces.  Read More

December 15, 2016

Repligen acquires TangenX Technology Corporation.  Read More

October 4, 2016

Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification.  Read More

April 4, 2016

Repligen acquires Atoll GmbH.  Read More


In the News

Press Contact

Sondra Newman
Senior Director, Investor Relations

press @

Phone: 781.250.0111
Toll-free: 800.622.2259
Fax: 781.250.0115

download repligen logo